GVS assessment of glucagon nasal powder (Baqsimi®) for the treatment of severe hypoglycaemia
The National Health Care Institute has completed its assessment whether glucagon nasal powder (Baqsimi®) for the treatment of severe hypoglycaemia in adults, adolescents and children aged 4 and over with diabetes mellitus can be included in the Medication Reimbursement System (GVS). The National Health Care Institute's advice is to include glucagon nasal powder (Baqsimi®) in List 1B of the GVS.
Registered indication
Glucagon nasal powder is indicated for the treatment of severe hypoglycaemia in adults, adolescents and children aged 4 and over with diabetes mellitus. It is available as a single-dose container with 3 mg of glucagon nasal powder. The recommended dose is 3 mg of glucagon administered in one nostril.
Interchangeability
In the GVS, the blood glucose-increasing medicinal product glucagon (Glucagen®, Glucagen hypokit®) is included for the indication ‘severe hypoglycaemia in diabetes mellitus’.
In the GVS, the classification of medicinal products into groups of interchangeability distinguishes between, among other criteria, medicinal products administered through injection and non-injection medicinal products.
For this reason, glucagon nasal powder and intramuscular glucagon are by definition not interchangeable. The National Health Care Institute sees added value for glucagon nasal powder because of its ease of use in acute situations, which prevents underuse of intramuscular glucagon.
The National Health Care Institute's advice
The National Health Care Institute advices the Minister of Medical Care to include glucagon nasal powder (Baqsimi®) on List 1B of the GVS.